Evidence map›Paper›PMID 26379549›Full record

ArticleFrontiers in pharmacology2015

Editorial: Improving the safety of cell therapy products by suicide gene transfer.

Elodie Bole-Richard, Marina Deschamps, Christophe Ferrand, Eric Robinet

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Genetically engineered T cells for cancer immunotherapy.Signal transduction and targeted therapy
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elodie Bole-RichardInstitut National de la Santé et de la Recherche Médicale UMR 1098, Etablissement Français du Sang Bourgogne/Franche-Comté Besançon, France ; SFR FRD 4234 Ingénierie et Biologie Cellulaire et Tissulaire, Université de Franche-Comté Besançon, France.
Marina DeschampsInstitut National de la Santé et de la Recherche Médicale UMR 1098, Etablissement Français du Sang Bourgogne/Franche-Comté Besançon, France ; SFR FRD 4234 Ingénierie et Biologie Cellulaire et Tissulaire, Université de Franche-Comté Besançon, France.
Christophe FerrandInstitut National de la Santé et de la Recherche Médicale UMR 1098, Etablissement Français du Sang Bourgogne/Franche-Comté Besançon, France ; SFR FRD 4234 Ingénierie et Biologie Cellulaire et Tissulaire, Université de Franche-Comté Besançon, France.
Eric RobinetInstitut National de la Santé et de la Recherche Médicale UMR 1110, Institut de Recherche sur les Maladies Virales et Hépatiques Strasbourg, France ; Institut Hospitalo-Universitaire de Strasbourg Strasbourg, France.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adoptive cell therapyadoptive immunotherapyherpes simplex virus thymidine kinaseinducible caspase 9suicide gene therapy

Identifiers

PMID26379549
PMCPMC4548201
OpenAlexW1567354324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.